- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
NeOnc Technologies: Stonegate updates coverage
New analysis spotlights NEO212's Phase 2-ready dose, NEO100's Phase 2 data and NeOnc's recent $16M PIPE, outlining its CNS brain tumor pipeline.
Mar. 12, 2026 at 12:52pm
Got story updates? Submit your updates here. ›
Stonegate Capital Partners has updated its coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier and improve drug delivery to the brain. The company's lead program, NEO212, is a next-generation version of temozolomide, the standard-of-care chemotherapy used in most brain cancer patients. Its platform also includes NEO100, a non-invasive drug delivery approach targeting recurrent glioblastoma. NeOnc recently completed a successful $16 million PIPE offering.
Why it matters
NeOnc's pipeline of novel CNS therapies targeting brain tumors represents a significant opportunity, as current treatments often struggle with blood-brain barrier penetration and drug resistance. The company's progress with NEO212 and NEO100, along with its recent capital raise, position it to advance its clinical programs and potentially improve outcomes for patients with these devastating diseases.
The details
NeOnc's lead program, NEO212, is designed to address key limitations of current brain cancer treatments, including blood-brain barrier penetration and MGMT-driven resistance. The company has completed a Phase 1 dose escalation study in recurrent glioblastoma, establishing a recommended Phase 2 dose of 610 mg and observing early signs of disease control. NEO100, NeOnc's intranasal therapy targeting recurrent glioblastoma, has shown promising Phase 2 data with radiographic responses and improved progression-free survival versus historical benchmarks. Additionally, NeOnc recently raised $16 million through a PIPE offering, bolstering its balance sheet to support the advancement of its CNS oncology pipeline.
- NeOnc completed a Phase 1 dose escalation study for NEO212 in recurrent glioblastoma.
- NeOnc established a recommended Phase 2 dose of 610 mg for NEO212.
- NeOnc reported promising Phase 2 data for its intranasal therapy, NEO100, in recurrent glioblastoma.
- NeOnc recently raised $16 million through a PIPE offering.
The players
NeOnc Technologies Holdings, Inc.
A clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier and improve drug delivery to the brain.
NEO212
NeOnc's lead program, a next-generation version of temozolomide designed to address key limitations of current brain cancer treatments.
NEO100
NeOnc's intranasal therapy targeting recurrent glioblastoma, with promising Phase 2 data showing radiographic responses and improved progression-free survival.
What’s next
NeOnc plans to advance NEO212 into a Phase 2 efficacy evaluation following the successful completion of the Phase 1 dose escalation study.
The takeaway
NeOnc's pipeline of novel CNS therapies targeting brain tumors, including the promising NEO212 and NEO100 programs, combined with its recent capital raise, position the company to make significant progress in addressing the significant unmet needs in the treatment of these devastating diseases.
